Başkent Üniversitesi Yayınları

Permanent URI for this communityhttps://hdl.handle.net/11727/13092

Browse

Filters

2008 - 20102

Settings

Subject: search.filters.subject.Chronic allograft dysfunction

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Risk Factors of Long-Term Graft Loss in Renal Transplant Recipients with Chronic Allograft Dysfunction
    (Başkent Üniversitesi, 2010-12) Khalkhali, Hamid Reza; Kazemnejad, Anoushirvan; Hajizadeh, Ebrahim; Ghafari, Ali
    Background: Graft loss owing to chronic allograft dysfunction is a major concern in renal transplant recipients. We assessed the affect of immune and nonimmune risk factors on death-censored graft loss in renal transplant recipients with chronic allograft dysfunction. Materials and Methods: We performed a retrospective, single-center study on 214 renal transplant recipients with chronic allograft dysfunction among 1534 renal transplant recipients at the Urmia University Hospital from 1997 to 2005. Data registry includes details from all renal transplants. The renal transplant recipient information is regularly updated to determine current graft function, graft loss, or renal transplant recipient’s death. The selection criteria were a functional renal allograft for at least 1 year and a progressive decline in allograft function. Results: Increasing donor age (RR=1.066; P < .001), recipient age (RR=1.021, P = .0), recipient weight (RR=1.024; P = .029), and waiting time on dialysis to transplant. (RR=1.047; P = .006), pretransplant hypertension (RR=3.126; P < .001), pretransplant diabetes (RR=5.787; P < .001), delayed graft function (RR=6.087; P < .001), proteinuria (RR=2.663; P = .001), posttransplant diabetes (RR=2.285; P = .015), posttransplant hypertension (RR=2.047; P = .017), and AR (RR=3.125; P < .001). Patients in stage 2 at the beginning of chronic allograft dysfunction relative to stage 1 (RR=4.823; P < .001) and patients in stage 3 at the beginning of chronic allograft dysfunction relative to stage 1 (RR=123.06; P < .001) were significant risk factors for death-censored graft loss. Using mycophenolate mofetil versus azathioprine reduced death-censored graft loss (RR=0.499; P ≤ .001). Conclusion: We found that age of donor, pretransplant hypertension, pretransplant diabetes, type of immunosuppression (mycophenolate mofetil vs azathioprine), delayed graft function, proteinuria, and stage of allograft dysfunction at the start of chronic allograft dysfunction are the major risk factors for late renal allograft dysfunction.
  • No Thumbnail Available
    Item
    Polymorphism of the Methylenetetrahydrofolate Reductase C677T Gene With Chronic Allograft Nephropathy in Renal Transplant Recipientsw
    (Başkent Üniversitesi, 2008-03) Azarpira, Negar; Darai, Masumeh; Raisjalali, Ghanbar
    Objectives: This study sought to investigate the frequency of the 5, 10-methylenetetrahydrofolate reductase gene (MTHFR C677T) in 127 patients (77 with chronic allograft nephropathy and 50 with normal renal function) who had undergone a renal transplant at least 20 months earlier to define the risk factors for chronic allograft dysfunction. Fifty healthy subjects served as controls. Materials and Methods: Genotypes were de­termined using polymerase chain reaction followed by restriction fragment length poly­morphism analysis. The restriction enzyme for the MTHFR C677T variants was HinfI. Results: No statistically significant differences were seen between the allelic and genotypic distribution of the MTHFR polymorphism. Conclusions: Additional studies with larger sample sizes are needed to define the influence of MTHFR C677T genotyping on clinical outcomes in renal allograft recipients.